

Zidovudine and lamivudine:

Class: Antiretroviral Agent, Reverse Transcriptase Inhibitor (Nucleoside)

Indications:

Treatment of HIV infection when therapy is warranted based on clinical and/or immunological evidence of disease progression

Available dosage form in the hospital: LAMIVUDINE 150MG +ZIDOVUDINE 300MG TAB.

Trade Names:

Dosage:

Treatment of HIV infection: Oral: 1 tablet twice daily. Because this is a fixed-dose combination product, avoid use in patients requiring dosage reduction including children <30 kg, renally-impaired patients with a creatinine clearance <50 mL/minute, hepatic impairment, or those patients experiencing dose-limiting adverse effects.

Common side effect:

For Zidovudine:

Central nervous system: Headache , malaise , fever .

Dermatologic: Rash .

Gastrointestinal: Nausea ,anorexia , vomiting .

Hematologic: Macrocytosis .

Hepatic: Hepatomegaly .

Respiratory: Cough .

Pregnancy Risk Factor: C